Upgrade to SI Premium - Free Trial

Valneva SE (VALN)

5.67 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/13/26)

Latest Headlines

Form 6-K Valneva SE For: Dec 31 June 5, 2026 6:36 AM - SEC Filing Form F-3 Valneva SE June 4, 2026 5:05 PM - SEC Filing Form 6-K Valneva SE For: Dec 31 June 1, 2026 10:00 AM - SEC Filing Form 6-K Valneva SE For: Mar 31 May 13, 2026 4:49 PM - SEC Filing Valneva SE (VLA:FP) (VALN) PT Lowered to EUR7.50 at Stifel May 13, 2026 9:17 AM - StreetInsider Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026 May 5, 2026 11:45 AM - Globe NewsWire Goldman Sachs Downgrades Valneva SE (VALN) to Sell April 22, 2026 12:53 AM - StreetInsider Goldman Sachs Downgrades Valneva SE (VLA:FP) (VALN) to Sell April 22, 2026 12:52 AM - StreetInsider Valneva SE (VALN) PT Lowered to $11 at Guggenheim April 16, 2026 7:14 AM - StreetInsider Valneva SE (VLA:FP) (VALN) PT Lowered to EUR5.60 at Kepler Cheuvreux March 26, 2026 5:02 AM - StreetInsider Valneva SE (VLA:FP) (VALN) PT Lowered to EUR8.50 at Stifel March 24, 2026 8:34 AM - StreetInsider Jefferies on Valneva SE (VALN): path to approval intact, 'weakness presents buying oppty' March 23, 2026 3:13 PM - StreetInsider Pfizer and Valneva's Lyme disease vaccine shows over 70% efficacy March 23, 2026 6:45 AM - StreetInsider Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial March 23, 2026 6:45 AM - BizWire Form 6-K Valneva SE For: Dec 31 March 18, 2026 11:22 AM - SEC Filing Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program March 18, 2026 8:00 AM - PR NewsWire Form 20-F Valneva SE For: Dec 31 March 17, 2026 4:38 PM - SEC Filing Form SCHEDULE 13D/A Valneva SE Filed by: Bpifrance Participations SA March 10, 2026 4:01 PM - SEC Filing Form 6-K Valneva SE For: Dec 31 March 9, 2026 12:51 PM - SEC Filing Full Article List